Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Identification of Novel Antigens Recognized by Serum Antibodies in Bovine Tuberculosis.

Lyashchenko KP, Grandison A, Keskinen K, Sikar-Gang A, Lambotte P, Esfandiari J, Ireton GC, Vallur A, Reed SG, Jones G, Vordermeier HM, Stabel JR, Thacker TC, Palmer MV, Waters WR.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00259-17. doi: 10.1128/CVI.00259-17. Print 2017 Dec.

2.

Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients.

Bezuneh A, Mukhtar M, Abdoun A, Teferi T, Takele Y, Diro E, Jemaneh A, Shiferaw W, Wondimu H, Bhatia A, Howard RF, Ghalib H, Ireton GC, Hailu A, Reed SG.

Am J Trop Med Hyg. 2014 Dec;91(6):1109-15. doi: 10.4269/ajtmh.13-0759. Epub 2014 Oct 13.

3.

Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosis.

Orr MT, Ireton GC, Beebe EA, Huang PW, Reese VA, Argilla D, Coler RN, Reed SG.

J Immunol. 2014 Sep 15;193(6):2911-8. doi: 10.4049/jimmunol.1401103. Epub 2014 Aug 1.

4.

The ID93 tuberculosis vaccine candidate does not induce sensitivity to purified protein derivative.

Baldwin SL, Reese V, Granger B, Orr MT, Ireton GC, Coler RN, Reed SG.

Clin Vaccine Immunol. 2014 Sep;21(9):1309-13. doi: 10.1128/CVI.00372-14. Epub 2014 Jul 16.

5.

Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis.

Shanley CA, Ireton GC, Baldwin SL, Coler RN, Reed SG, Basaraba RJ, Orme IM.

Tuberculosis (Edinb). 2014 Mar;94(2):140-7. doi: 10.1016/j.tube.2013.08.010. Epub 2013 Sep 7.

6.

Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.

Jones GJ, Steinbach S, Clifford D, Baldwin SL, Ireton GC, Coler RN, Reed SG, Vordermeier HM.

Vaccine. 2013 Oct 25;31(45):5250-5. doi: 10.1016/j.vaccine.2013.08.051. Epub 2013 Sep 5.

7.

Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.

Ireton GC, Reed SG.

Expert Rev Vaccines. 2013 Jul;12(7):793-807. doi: 10.1586/14760584.2013.811204. Review.

PMID:
23885824
8.

Development and pre-clinical assessment of a 73 kD chimeric fusion protein as a defined sub-unit vaccine for leprosy.

Duthie MS, Sampaio LH, Oliveira RM, Raman VS, O'Donnell J, Bailor HR, Ireton GC, Sousa AL, Stefani MM, Reed SG.

Vaccine. 2013 Jan 21;31(5):813-9. doi: 10.1016/j.vaccine.2012.11.073. Epub 2012 Dec 8.

PMID:
23228811
9.

Immunologically reactive M. leprae antigens with relevance to diagnosis and vaccine development.

Sampaio LH, Stefani MM, Oliveira RM, Sousa AL, Ireton GC, Reed SG, Duthie MS.

BMC Infect Dis. 2011 Jan 26;11:26. doi: 10.1186/1471-2334-11-26.

10.

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG.

Sci Transl Med. 2010 Oct 13;2(53):53ra74. doi: 10.1126/scitranslmed.3001094.

11.

Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value.

Ireton GC, Greenwald R, Liang H, Esfandiari J, Lyashchenko KP, Reed SG.

Clin Vaccine Immunol. 2010 Oct;17(10):1539-47. doi: 10.1128/CVI.00198-10. Epub 2010 Aug 18.

12.

Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants.

Fox CB, Friede M, Reed SG, Ireton GC.

Subcell Biochem. 2010;53:303-21. doi: 10.1007/978-90-481-9078-2_14.

PMID:
20593273
13.

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.

Baldwin SL, Bertholet S, Kahn M, Zharkikh I, Ireton GC, Vedvick TS, Reed SG, Coler RN.

Vaccine. 2009 May 18;27(23):3063-71. doi: 10.1016/j.vaccine.2009.03.018. Epub 2009 Mar 26.

14.

Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Kahn M, Guderian J, Mohamath R, Stride N, Laughlin EM, Baldwin SL, Vedvick TS, Coler RN, Reed SG.

J Immunol. 2008 Dec 1;181(11):7948-57.

15.

Antigen-specific T-cell responses of leprosy patients.

Duthie MS, Goto W, Ireton GC, Reece ST, Sampaio LH, Grassi AB, Sousa AL, Martelli CM, Stefani MM, Reed SG.

Clin Vaccine Immunol. 2008 Nov;15(11):1659-65. doi: 10.1128/CVI.00234-08. Epub 2008 Sep 10.

16.

Selection of antigens and development of prototype tests for point-of-care leprosy diagnosis.

Duthie MS, Ireton GC, Kanaujia GV, Goto W, Liang H, Bhatia A, Busceti JM, Macdonald M, Neupane KD, Ranjit C, Sapkota BR, Balagon M, Esfandiari J, Carter D, Reed SG.

Clin Vaccine Immunol. 2008 Oct;15(10):1590-7. doi: 10.1128/CVI.00168-08. Epub 2008 Aug 20.

17.

Use of protein antigens for early serological diagnosis of leprosy.

Duthie MS, Goto W, Ireton GC, Reece ST, Cardoso LP, Martelli CM, Stefani MM, Nakatani M, de Jesus RC, Netto EM, Balagon MV, Tan E, Gelber RH, Maeda Y, Makino M, Hoft D, Reed SG.

Clin Vaccine Immunol. 2007 Nov;14(11):1400-8. Epub 2007 Sep 26.

18.

Antigen-specific cellular and humoral responses are induced by intradermal Mycobacterium leprae infection of the mouse ear.

Duthie MS, Reece ST, Lahiri R, Goto W, Raman VS, Kaplan J, Ireton GC, Bertholet S, Gillis TP, Krahenbuhl JL, Reed SG.

Infect Immun. 2007 Nov;75(11):5290-7. Epub 2007 Aug 27.

19.

Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy.

Mahan SD, Ireton GC, Knoeber C, Stoddard BL, Black ME.

Protein Eng Des Sel. 2004 Aug;17(8):625-33. Epub 2004 Sep 20.

PMID:
15381761
20.

Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference.

Mahan SD, Ireton GC, Stoddard BL, Black ME.

Biochemistry. 2004 Jul 20;43(28):8957-64.

PMID:
15248753
21.

Microseed matrix screening to improve crystals of yeast cytosine deaminase.

Ireton GC, Stoddard BL.

Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):601-5. Epub 2004 Feb 25. Erratum in: Acta Crystallogr D Biol Crystallogr. 2004 Apr;60(4):801.

PMID:
14993707
22.

Design of a novel globular protein fold with atomic-level accuracy.

Kuhlman B, Dantas G, Ireton GC, Varani G, Stoddard BL, Baker D.

Science. 2003 Nov 21;302(5649):1364-8.

24.

The structure of Escherichia coli cytosine deaminase.

Ireton GC, McDermott G, Black ME, Stoddard BL.

J Mol Biol. 2002 Jan 25;315(4):687-97.

PMID:
11812140
25.

Crystallization and preliminary X-ray analysis of bacterial cytosine deaminase.

Ireton GC, Black ME, Stoddard BL.

Acta Crystallogr D Biol Crystallogr. 2001 Nov;57(Pt 11):1643-5. Epub 2001 Oct 25.

PMID:
11679731
26.
27.
28.

Reconstitution of human topoisomerase I by fragment complementation.

Stewart L, Ireton GC, Champoux JJ.

J Mol Biol. 1997 Jun 13;269(3):355-72.

PMID:
9199405
29.

The domain organization of human topoisomerase I.

Stewart L, Ireton GC, Champoux JJ.

J Biol Chem. 1996 Mar 29;271(13):7602-8.

30.

Biochemical and biophysical analyses of recombinant forms of human topoisomerase I.

Stewart L, Ireton GC, Parker LH, Madden KR, Champoux JJ.

J Biol Chem. 1996 Mar 29;271(13):7593-601.

Supplemental Content

Loading ...
Support Center